Curated News
By: NewsRamp Editorial Staff
November 12, 2026
Cardio Diagnostics Releases Whitepaper on NOCAD and INOCA
TLDR
- Cardio Diagnostics released a whitepaper on NOCAD, positioning its AI-driven PrecisionCHD test as a competitive advantage in early detection.
- The whitepaper examines NOCAD and INOCA, highlighting how Cardio Diagnostics' AI and epigenetics-based blood test, PrecisionCHD, aids diagnosis.
- Cardio Diagnostics' whitepaper aims to improve detection of NOCAD, potentially helping millions by enabling earlier, more accurate diagnosis and care.
- Cardio Diagnostics' whitepaper explores INOCA, affecting 3-4 million Americans, and the potential of epigenetics-based testing in primary care.
Impact - Why it Matters
This news matters because NOCAD and INOCA affect millions of Americans whose symptoms are often missed by standard angiography, leading to delayed diagnosis and treatment. By highlighting the limitations of traditional imaging and proposing epigenetics-based blood tests like PrecisionCHD, Cardio Diagnostics aims to enable earlier, non-invasive detection in primary care. If validated, this approach could transform how coronary heart disease is identified, especially in patients without obstructive blockages, potentially reducing unnecessary procedures and improving outcomes. The whitepaper also underscores the growing role of AI and epigenetics in precision cardiovascular medicine, signaling a shift toward more personalized and accessible diagnostics.
Summary
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, has released a whitepaper addressing diagnostic challenges in non-obstructive coronary artery disease (NOCAD), a condition where patients experience coronary disease symptoms without significant blockages in major arteries. The whitepaper focuses on limitations of invasive coronary angiography, which assesses anatomy rather than function, and highlights ischemia with no obstructive coronary arteries (INOCA), affecting an estimated 3 million to 4 million Americans. It also outlines clinical approaches to identify patients earlier, including the potential role of epigenetics-based testing in primary care.
The whitepaper examines NOCAD subgroups, diagnostic pathways, and opportunities to improve detection of coronary disease that may not be identified through conventional angiography. Cardio Diagnostics also highlighted its ongoing efforts to build clinical evidence supporting PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease, including its potential application in identifying patients with INOCA whose symptoms remain unexplained by traditional testing. To view the full press release, visit https://ibn.fm/N5RnS.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Cardio Diagnostics Releases Whitepaper on NOCAD and INOCA
